Quantcast
Channel: WN.com - Articles related to U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia
Viewing all articles
Browse latest Browse all 270

Young adult patients* with schizophrenia show improved functioning and health-related quality of life with Abilify Maintena® (aripiprazole once-monthly) compared with paliperidone palmitate (H Lundbeck A/S)

$
0
0
(Source: H Lundbeck A/S) Valby, 2015-06-23 17:47 CEST (GLOBE NEWSWIRE) -- For non-US media only • A newly released pre-specified subgroup analysis from the QUALIFY** study shows that younger adult patients* improve significantly on aripiprazole once-monthly compared with paliperidone palmitate as measured by the Heinrichs-Carpenter Quality of Life Scale (QLS).1 • The positive effect of aripiprazole once-monthly is seen consistently in this subgroup of younger patients* across a range of effectiveness measures, suggesting that aripiprazole once-monthly treatment at a younger age may confer better treatment outcomes than paliperidone palmitate in patients with schizophrenia.1 • Results from...

Viewing all articles
Browse latest Browse all 270

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>